Abstract:Pedro Luiz Serrano Uson Junior 1,2,3 , Mitesh J. Borad 1 1 Division of Hematology/Oncology, Mayo Clinic Cancer Center, Mayo Clinic, Phoenix, AZ, USA; 2 Division of Hematology/Oncology, Hospital do Coração, HCOR, Sao Paulo, Brazil; 3 Center for Personalized Medicine, Hospital Israelita Albert Einstein, Sao Paulo, Brazil Comment on: Nakachi K, Ikeda M, Konishi M, et al . Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet 2023;401:195-203. Keywords: Capecitabine; biliary tract cancer (BTC); S1; fluoropyrimidines Submitted Jun 17, 2024. Accepted for publication Aug 28, 2024. Published online Sep 27, 2024. doi: 10.21037/tcr-24-1007 We read with great interest the article published by Nakachi et al. , a randomized phase III trial that evaluated adjuvant treatment with S-1 for 24 weeks or observation in resected biliary tract cancers (BTC) (1). This trial is very important considering that other chemotherapy regimens including gemcitabine and gemcitabine plus oxaliplatin were evaluated in randomized trials in the same scenario with negative results (2,3). BTCs are a group of malignancies that arises from the bile ducts or gallbladder. Although rare, more than half of the cases can be diagnosed in advanced stages and the overall prognosis is poor (1). Patients submitted to surgery can be treated with adjuvant chemotherapy, however the data of trials are contradictory (2-7). Also, it is very common surgical specimens with locally advanced disease with positive lymph nodes and not complete resections in the trials (1-8). Two trials were positive with oral fluoropyrimidines in the adjuvant setting. In this editorial we will address and compare both trials. The ASCOT study was a randomized phase III trial conducted in 38 Japanese hospitals and included patients with cholangiocarcinoma, gallbladder, and ampullary cancers that underwent resection (1). Patients were randomized to the observation group or to receive S-1, orally administered twice daily for 4 weeks, followed by 2 weeks of rest for four cycles (1). The study was conducted between 2013 and 2018, and a total of 440 patients were randomized between the two arms, with a data cutoff date of June 23, 2021 (1). The trial met its primary endpoint, with improvements in 3-year overall survival (OS) of 77.1% [95% confidence interval (CI): 70.9–82.1%] in the S-1 group, compared with 67.6% (95% CI: 61.0–73.3%) in the observation group [hazard ratio (HR) 0.69, 95% CI: 0.51–0.94; one-sided P=0.008]. Furthermore, improvements in relapse-free survival (RFS) were also observed; 3-year RFS was 62.4% (95% CI: 55.6–68.4%) in the S-1 group compared to 50.9% (95% CI: 44.1–57.2%) in the observation group (HR 0.80, 95% CI: 0.61–1.04; two-sided P=0.088) (1). The toxicity associated with S-1 was manageable, including biliary tract infection (7%) and decreased neutrophil count (14%), which are more common grades 3–4 adverse events (AEs) (1). Before this trial, adjuvant treatment for resected BTC had been investigated multiple times (4). A meta-analysis, including twenty studies with more than 6 thousand patients evaluated, concluded that adjuvant systemic treatments in resected BTC could improve OS, particularly in node-positive and margin-positive cases (4). However, when all the studies were evaluated, including two registry studies, the meta-analysis was negative (4). More recently, the BILCAP trial was the first to show some improvements in OS with adjuvant chemotherapy in resected BTC (5). The trial was conducted in the United Kingdom; a total of 44 centers participated in the recruitment. It was a controlled, randomized trial. The study randomized resected BTC (cholangiocarcinoma or gallbladder) patients to receive oral capecitabine twice daily on days 1–14 of a 21-day cycle, for eight cycles, or observation. A total of 447 patients were included between 2006 and 2014, with the data cutoff date of March 6, 2017 (5). The study did not meet its primary endpoint, with a median OS by intention-to-treat (ITT) of 51.1 months (95% CI: 34.6–59.1) in the capecitabine group compared to 36.4 months (29.7–44.5) in the observation group (HR 0.81, 95% CI: 0.63–1.04; P=0.097) (5). However, after a sensitivity analysis adjusting for nodal status, sex, and disease grade, the study was positive for improving median OS (HR 0.71, 95% CI: 0.55–0.92; P=0.010). Furthermore, the ITT median RFS was longer with capecitabine than with observation, at 24.4 months (95% CI: 18.6–35.9) versus 17.5 months (12.0–23.8), particularly in the first 2 years (HR 0.75, 95% CI: 0.58–0.98; P=0.033) (5). There are some points that these two randomized controlled trials have in common and some points that are misaligned. First, both -Abstract Truncated-

Adjuvant Tislelizumab Combined with Capecitabine for Patients with Biliary Tract Cancer with High Risk of Postoperative Relapse (ACTIVE): Primary Analysis from a Prospective Cohort Study.

Efficacy and safety of camrelizumab, apatinib, and capecitabine combination therapy in advanced biliary tract cancer: a phase 2, nonrandomized, prospective study

Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study

A Single-Arm Phase II Study of Nab-Paclitaxel Plus Gemcitabine and Cisplatin for Locally Advanced or Metastatic Biliary Tract Cancer.

Tislelizumab Plus Sitravatinib As Adjuvant Therapy for Patients with Hepatocellular Carcinoma at High Risk of Recurrence after Surgical Resection: Preliminary Analysis of a Multi-Center, Non-Randomized, Open-Label Phase 2 Study.

Immune Checkpoint Inhibitors (icis) Plus CAPOX in the Treatment of Unresectable Advanced or Recurrent Biliary Tract Carcinoma (BTC): A Retrospective Study.

ZSAB-TOP: A Phase 2 Trial of Tislelizumab (TIS) and Ociperlimab (OCI) Combined with Gemcitabine and Cisplatin (gemcis) As the First-Line Treatment for Advanced Biliary Tract Cancer (BTC).

Adjuvant treatment in resected biliary cancers: fluoropyrimidines on the spotlight

Tislelizumab in Combination with GEMOX and Lenvatinib for Conversion Therapy of Unresectable Extrahepatic Biliary Tract Carcinoma (ebtc): A Prospective, Single-Arm, Phase 2 Study.

Abstract GS1-08: Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (cbcsg010): An open-label, randomised, multicentre, phase 3 trial

A phase II study of tremelimumab, durvalumab, and bevacizumab in advanced biliary tract cancers.

Toripalimab with chemotherapy as first-line treatment for advanced biliary tract tumors: Update analytic results of an open-label phase II clinical study (JS001-ZS-BC001).

Nab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers: An open-label, non-randomized, phase II clinical trial

A Phase 3, Randomized Study of Adjuvant Rilvegostomig Plus Chemotherapy in Resected Biliary Tract Cancer: ARTEMIDE-Biliary01.

53P Toripalimab with chemotherapy as first-line treatment for advanced biliary tract tumors: A preliminary analysis of safety and efficacy of an open-label phase II clinical study

Immune Checkpoint Inhibitors Plus Capecitabine and Oxaliplatin in Unresectable or Advanced Biliary Tract Cancer Patients: A Retrospective Study.

TisCRT-LAPC: A Phase II Study of Tislelizumab Combined with Nab-Paclitaxel and Gemcitabine (AG) Followed by Consolidative Radiotherapy in Locally Advanced Pancreatic Cancer (LAPC).

A prospective, single-arm, phase II clinical study of tislelizumab in combination with lenvatinib for perioperative treatment of resectable primary hepatocellular carcinoma with high risk of recurrence.

Efficacy and safety of a combination of sintilimab, bevacizumab plus gemcitabine, and albumin-bound paclitaxel for initially unresectable gallbladder carcinoma: A prospective, single-arm phase II study.

A Retrospective Cohort Study Of Anti-Pd-1 Therapy Combined With Chemotherapy In Patients With Advanced Biliary Tract Cancer.

A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary tract cancer